4820 Richard Road SW
Suite 300
Calgary, AB T3E 6L1
Canada
403-254-9252
https://www.resverlogix.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Donald J. McCaffrey | Co-Founder, Chairman, President, CEO & Secretary | 505,2k | N/A | N/A |
Mr. Aaron Bradley Cann C.A., CPA, CBV | Chief Financial Officer | 281,8k | N/A | N/A |
Dr. Ewelina Kulikowski Ph.D. | Chief Scientific Officer | 250k | N/A | N/A |
Dr. Michael Sweeney M.D. | Senior Vice President of Clinical Development | 511,56k | N/A | 1961 |
Sarah Zapotichny | Director of Investor Relations & Corporate Communications | N/A | N/A | N/A |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company is headquartered in Calgary, Canada.
Resverlogix Corp.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.